Plain-English translation of NCT06125652 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing , a treatment that uses your own immune cells (T cells) to fight leukemia. The therapy is designed to recognize and attack leukemia stem cells — the cells that drive the cancer — while being gentler on your healthy blood cells. This approach aims to reduce serious side effects seen with other similar treatments.
Current immune cell therapies targeting leukemia can accidentally damage healthy blood cells and bone marrow, causing severe infections, bleeding, and organ problems. This trial exists to test whether targeting two specific markers (Tim-3 and CD123) instead of just one could make the treatment safer and more effective.
You likely qualify if…
You likely don't qualify if…
You will receive a treatment where doctors collect your own T cells (immune cells), genetically modify them in the laboratory to recognize leukemia cells, and then infuse them back into your body. The study involves clinical visits for monitoring, blood tests, and imaging to assess how the treatment is working and watch for any side effects. The trial is currently enrolling up to 20 participants and will track your response and safety over time.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China
Phase
Safety & dosing / Early efficacy
Sponsor
Xuzhou Medical University
Enrollment target
~20 participants
Started
November 2023
Primary completion
January 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in November 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Kailin Xu, MD.,PD.
The Affiliated Hospital oh Xuzhou Medical University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.